The state of play of therapeutic cannabis in France
The adoption of medical cannabis is progressing cautiously in our country, framed by strict rules which limit it to very specific cases, in particular certain types of cancers, drug-dependent forms of epilepsy or even multiple sclerosis.
It is in this context that the initiative of DelleD, founded in 2014 by Franck Milone, takes place. Established since October 2020 in Angers, the company is today the only one in France to cultivate, transform and market products derived from medical cannabis, in strict compliance with the standards imposed by the ANSM ( National Medicines Safety Agency).
Collaborating with the CNRS of Strasbourg since 2017 for the development of drugs, Delled – LaFleur only obtained authorization to start its clinical trials in 2021, in the wake of the major experiment carried out by the Ministry of Health. More than 3,000 patients facing treatment failure are targeted.
This experiment focuses exclusively on patients in the palliative phase, suffering from pain resistant to conventional treatments, neuropathic or oncological, as well as on individuals suffering from forms severe epilepsy.
If therapeutics advance cautiously, consumer CBD thrives
In France, some 7 million consumers have already succumbed to the hemp pleasures of CBD! Legalized at the end of 2020 in all EU countries by decision of the European Court of Justice, this natural molecule extracted from the hemp plant has found its place in the daily lives of consumers for three main reasons:
Its soothing properties help affected organisms to better fight stress and anxiety;
Its relaxing effects promote a good night's sleep, especially for those experiencing episodes of insomnia;
CBD is an excellent natural painkiller. It helps soothe acute or chronic pain of mild to moderate intensity, naturally.
